ProfileGDS5678 / 1428413_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 80% 76% 75% 75% 77% 74% 76% 76% 79% 75% 75% 79% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0632276
GSM967853U87-EV human glioblastoma xenograft - Control 25.6774580
GSM967854U87-EV human glioblastoma xenograft - Control 35.150376
GSM967855U87-EV human glioblastoma xenograft - Control 45.0519575
GSM967856U87-EV human glioblastoma xenograft - Control 55.040975
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0515477
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7273874
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0609976
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0871776
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5910779
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9838675
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0634475
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4288379
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7512274